KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Operating Leases (2019 - 2026)

GoodRx Holdings' Operating Leases history spans 7 years, with the latest figure at $54.5 million for Q4 2025.

  • On a quarterly basis, Operating Leases rose 18.47% to $54.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $54.5 million, a 18.47% increase, with the full-year FY2025 number at $54.5 million, up 18.47% from a year prior.
  • Operating Leases hit $54.5 million in Q4 2025 for GoodRx Holdings, up from $51.3 million in the prior quarter.
  • Over the last five years, Operating Leases for GDRX hit a ceiling of $56.3 million in Q1 2023 and a floor of $32.0 million in Q3 2021.
  • Historically, Operating Leases has averaged $44.7 million across 5 years, with a median of $48.0 million in 2023.
  • Biggest five-year swings in Operating Leases: skyrocketed 73.1% in 2023 and later decreased 12.75% in 2025.
  • Tracing GDRX's Operating Leases over 5 years: stood at $33.6 million in 2021, then surged by 61.14% to $54.1 million in 2022, then dropped by 10.58% to $48.4 million in 2023, then dropped by 4.88% to $46.0 million in 2024, then increased by 18.47% to $54.5 million in 2025.
  • Business Quant data shows Operating Leases for GDRX at $54.5 million in Q4 2025, $51.3 million in Q3 2025, and $52.7 million in Q2 2025.